S. Alberts

发表

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

D. Sargent, S. Thibodeau, R. Goldberg, 2012, JAMA.

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

R. Labianca, D. Kerr, D. Sargent, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

P. Novotny, J. Sloan, C. Loprinzi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

D. Sargent, P. Laurent-Puig, R. Goldberg, 2017, JAMA oncology.

Role of Deficient DNAMismatch Repair Status in PatientsWith Stage III Colon Cancer Treated With FOLFOXAdjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials

D. Sargent, P. Laurent-Puig, R. Goldberg, 2017 .

Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

M. Barrett, M. Borad, C. Moser, 2016, Cancer letters.

Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS FNA) Detection of Malignant Iliac Lymph Nodes in Rectal Cancer

Kenneth K Wang, H. Nelson, A. Clayton, 2006 .

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

J. Berlin, A. Venook, S. Alberts, 2013, Annals of Surgical Oncology.

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.

R. Schilsky, A. Benson, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors

N. Foster, S. Alberts, A. Jatoi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer.

A. Zinsmeister, J. Murray, S. Alberts, 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group

K. Rowland, S. Alberts, M. Mahoney, 2004, International seminars in surgical oncology : ISSO.

Treatment advances in liver-limited metastatic colorectal cancer.

S. Alberts, G. Poston, 2011, Clinical colorectal cancer.

Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma

S. Alberts, M. Mahoney, P. Flynn, 2005, Cancer.

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

S. Mandrekar, G. Wilding, S. Alberts, 2005, Clinical Cancer Research.

APhase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor , PS-341 ( Bortezomib , Velcade ) , in Patientswith Advanced Cancer

S. Alberts, H. Pitot, C. Erlichman, 2005 .

Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma

G. Gores, S. Nyberg, S. Alberts, 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Long-term Results of a Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Treatment in Advanced Head and Neck and Esophageal Malignancies

J. Sarkaria, V. Lowe, S. Alberts, 2017 .

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.

D. Moore, N. Foster, K. Rowland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.

N. Foster, S. Dakhil, S. Alberts, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial

A. Grothey, K. Rowland, L. Hart, 2008 .

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

P. Novotny, J. Sloan, C. Loprinzi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.

D. Sargent, J. Donohue, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NO147: A Randomized Phase III Trial of Oxaliplatin Plus 5-Fluorouracil, and Leucovorin (Modified FOLFOX6) with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer

S. Alberts, F. Sinicrope, 2008 .

N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.

A. Grothey, S. Alberts, F. Sinicrope, 2005, Clinical colorectal cancer.

A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

J. Sloan, R. Goldberg, A. Adjei, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin in the Treatment of Colorectal Cancer

R. Goldberg, S. Alberts, S. Jacobson, 2002 .

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.

D. Nagorney, T. Smyrk, M. O’connell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.

Minetta C. Liu, M. Borad, T. Bekaii-Saab, 2019, The oncologist.

Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases.

S. Alberts, C. Deschamps, Amanda C Ashley, 2006, Clinical colorectal cancer.

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

J. Sloan, L. Denis, S. Alberts, 2006, Cancer Chemotherapy and Pharmacology.

Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.

D. Sargent, C. Fuchs, R. Goldberg, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

J. Sloan, R. Diasio, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Management Chapter 13: Colon, rectal, and anal cancers

D. Citrin, S. Alberts, P. Das, 2010 .

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

P. Catalano, A. Benson, S. Alberts, 2005 .

Prospective Evaluation of a 12‐Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer

S. Alberts, M. Lopatin, N. Zhang, 2017, Clinical colorectal cancer.

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

P. Philip, S. Alberts, Z. Wainberg, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

J. Hainsworth, A. Grothey, L. Hart, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma.

S. Alberts, 2000, Oncology.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

P. Catalano, A. Benson, S. Alberts, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New adjuvant therapy for colon cancer: justified hope or commercial hype.

M. O’connell, E. Galanis, S. Alberts, 2000, Surgical oncology clinics of North America.

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Michael Barnes, Azita Djalilvand, S. Alberts, 2018, Clinical Cancer Research.

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.

D. Sargent, S. Thibodeau, P. Laurent-Puig, 2015 .

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Daniel J Sargent, D. Sargent, C. Fuchs, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accomplishments in 2007 in the management of curable metastatic colorectal cancer.

S. Alberts, R. Adam, Amit Shah, 2008, Gastrointestinal cancer research : GCR.

Incremental costs of enrolling cancer patients in clinical trials: a population-based study.

S. Cha, C. Chute, J. Killian, 1999, Journal of the National Cancer Institute.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

D. Sargent, M. Delorenzi, R. Lothe, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Transplantation for hilar cholangiocarcinoma

G. Gores, S. Nyberg, S. Alberts, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma

G. Gores, W. Kremers, D. Nagorney, 2005, Annals of surgery.

Gastric cancer: epidemiology, pathology and treatment.

C. V. D. van de Velde, S. Alberts, A. Cervantes, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.

N. Foster, K. Rowland, S. Alberts, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Collateral damage of COVID-19 pandemic on oncology clinical trials.

S. Alberts, R. McWilliams, A. Mahipal, 2020, Chinese Clinical Oncology.

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.

P. Novotny, J. Sloan, C. Loprinzi, 2007, Mayo Clinic proceedings.

Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial

P. Novotny, J. Sloan, C. Loprinzi, 2006 .

Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study.

E. Perez, K. Rowland, S. Alberts, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of estrogen receptor determinations by a biochemical ligand‐binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials

H. Wieand, J. Ingle, J. Krook, 1996, Cancer.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

J. Sloan, R. Marks, R. Goldberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol

G. Gores, W. Kremers, S. Alberts, 2015, Transplant international : official journal of the European Society for Organ Transplantation.

Occurrence of esophageal and gastric cancer in Alaska Natives, 1969-2003.

S. Alberts, A. Lanier, F. Sacco, 2006, Alaska medicine.

Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial

S. Dakhil, S. Alberts, S. Nair, 2012, American journal of clinical oncology.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

S. Cha, R. Labianca, D. Sargent, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In reply [8]

D. Sargent, C. Loprinzi, S. Alberts, 2005 .

Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.

D. Nagorney, M. O’connell, S. Alberts, 2012, Clinical colorectal cancer.

Erroneous Sentence Removed From Article.

S. Alberts, F. Sinicrope, Qian Shi, 2017, JAMA oncology.

Error in Author Degree.

S. Alberts, F. Sinicrope, Qian Shi, 2017, JAMA dermatology.

Mutation in BRAF V600E-Reply.

S. Alberts, F. Sinicrope, Q. Shi, 2017, JAMA oncology.

N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study.

D. Sargent, C. Fuchs, R. Goldberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

E. Perez, J. Sloan, C. Loprinzi, 2009, Breast Cancer Research and Treatment.

High-Folate Diets and Breast Cancer Survival in a Prospective Cohort Study

D. Grabrick, J. Cerhan, R. Vierkant, 2002, Nutrition and cancer.

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).

Michael Barnes, Azita Djalilvand, S. Alberts, 2018 .

Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147).

D. Sargent, J. Sloan, R. Diasio, 2012 .

Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, E. Basch, J. Sloan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].

D. Sargent, S. Thibodeau, R. Goldberg, 2014 .

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).

D. Sargent, R. Goldberg, A. Shields, 2017 .

Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

G. Gores, S. Nyberg, S. Alberts, 2004, Seminars in liver disease.

Predictors of Disease Recurrence Following Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

G. Gores, W. Kremers, S. Nyberg, 2006, Transplantation.

Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer

R. Goldberg, T. Smyrk, N. Foster, 2021, JNCI cancer spectrum.

Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group

N. Foster, J. Kugler, S. Alberts, 2005, Supportive Care in Cancer.

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

J. Sloan, R. Goldberg, S. Alberts, 2005, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

S. Mandrekar, S. Alberts, H. Pitot, 2006, Cancer Chemotherapy and Pharmacology.

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.

P. Schaefer, N. Foster, J. Kugler, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Low level of hepatitis B virus screening among patients receiving chemotherapy.

W. Kim, J. Larson, S. Alberts, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.

R. Weinshilboum, M. Goetz, R. Goldberg, 2007, Clinical colorectal cancer.

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Tumor-infiltrating Lymphocytes (TILs) with Survival Depends on Primary Tumor Sidedness in Stage III Colon Cancers (NCCTG N0147) [Alliance].

N. Foster, S. Alberts, F. Sinicrope, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

A. Benson, S. Alberts, H. Cárdenes, 2008 .

Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma

Nguyen H. Tran, M. Borad, T. Bekaii-Saab, 2022, Targeted Oncology.

Antigen presenting cell based immunotherapy targeting HER2/Neu positive solid tumors: Results of a phase 1 study of APC8024.

S. Alberts, K. Rinn, L. Jones, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of the National Cancer Institute.

Oxaliplatin in the Treatment of Colorectal Cancer

R. Goldberg, S. Alberts, S. Jacobson, 2002 .

Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.

C. Willett, C. Fuchs, J. Tepper, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).

R. Labianca, D. Kerr, D. Sargent, 2014 .

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

S. Cha, D. Sargent, D. Moore, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.

S. Cha, D. Sargent, D. Moore, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Daniel J Sargent, Greg Yothers, Qian Shi, 2013, Clinical colorectal cancer.

N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU

D. Sargent, P. Philip, R. Goldberg, 2005 .

Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy

D. Sargent, P. Philip, R. Goldberg, 2005 .

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study.

D. Sargent, C. Fuchs, R. Goldberg, 2004, Journal of Clinical Oncology.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019 .

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

N. Wolmark, E. Van Cutsem, R. Goldberg, 2019, Journal of Clinical Oncology.

E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis.

D. Cella, A. Benson, S. Alberts, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147

D. Sargent, S. Alberts, A. Jatoi, 2008, Oncology.

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

A. Benson, J. Galon, R. Goldberg, 2022, JCO precision oncology.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, A. Benson, J. Galon, 2018 .

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

D. Sargent, A. Benson, J. Galon, 2017 .

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

E. Van Cutsem, R. Goldberg, D. Haller, 2020 .

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Journal of Clinical Oncology.

N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma

N. Foster, S. Dakhil, S. Alberts, 2022, The oncologist.

Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia: A phase II study from the North Central Cancer Treatment Group

N. Foster, J. Kugler, S. Alberts, 2005 .

A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia

D. Sargent, R. Goldberg, K. Rowland, 2002, International journal of gastrointestinal cancer.

Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943

N. Foster, J. Kugler, S. Alberts, 2007, Journal of gastrointestinal cancer.

Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201).

J. Berlin, D. Cella, A. Benson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide therapy in adult patients with myelodysplastic syndrome

S. Alberts, A. Tefferi, S. Geyer, 2006, Cancer.

Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).

Tsung-Teh Wu, D. Wigle, S. Alberts, 2021, European journal of cancer.

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

J. Jett, J. Sloan, R. Goldberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.

P. Philip, S. Alberts, Z. Wainberg, 2014 .

Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147

D. Sargent, S. Thibodeau, R. Goldberg, 2010 .

Treatment endpoints for advanced cholangiocarcinoma

G. Gores, T. Baron, S. Alberts, 2004, Nature Clinical Practice Gastroenterology &Hepatology.

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

B. Costello, M. Borad, S. Alberts, 2014, Investigational New Drugs.

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer

J. Grilley-Olson, S. Alberts, C. Xia, 2018, British Journal of Cancer.

Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials.

D. Sargent, N. Foster, S. Dakhil, 2010, International journal of oncology.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

J. Sicklick, J. Vauthey, A. Benson, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer

J. Sloan, C. Loprinzi, S. Alberts, 2003, Breast Cancer Research and Treatment.

Gemcitabine and Docetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial

S. Alberts, G. Farr, J. Reid, 2012, American journal of clinical oncology.

Current Utilization and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer

S. Alberts, M. Mahoney, B. Pockaj, 2017 .

' Phase J, study of the matrix metalloproteinase inhibitor, BAY 12-956^

J. Sloan, R. Goldberg, S. Alberts, 2001 .

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

J. Sloan, R. Goldberg, S. Alberts, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841.

D. Sargent, R. Goldberg, A. Grothey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2019, Journal of Clinical Oncology.

Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014 .

Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone

B. Petersen, Kenneth K Wang, N. Takahashi, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results

N. Foster, J. Kugler, S. Alberts, 2007 .

SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).

Charles R. Thomas, L. Dawson, M. Thomas, 2014 .

Phase II Trial of KW2189 in Patients With Advanced Malignant Melanoma

S. Alberts, V. Suman, A. Adjei, 2002, American journal of clinical oncology.

Cancer evention esearch arch Article s of Inositol Polyphosphate 5-Phosphatase Is an Early nt in Development of Cutaneous Squamous Pr R l Carcinoma

M. Bittner, J. Trent, G. Hostetter, 2010 .

Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial

S. Alberts, H. Pitot, V. Suman, 2007, Journal of gastrointestinal cancer.

Alternate dosing of cetuximab for patients with metastatic colorectal cancer.

S. Alberts, J. Hubbard, 2013, Gastrointestinal cancer research : GCR.

Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)

P. Novotny, J. Sloan, C. Loprinzi, 2012, Cancer.

Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).

T. Smyrk, N. Foster, S. Alberts, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.

M. Blute, S. Alberts, 2001, Urology.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

D. Sargent, M. Shah, D. Haller, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

C. Compton, D. Kerr, M. Bertagnolli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer of the Stomach

S. Alberts, L. Gunderson, J. Donohue, 2008 .

Predictive Biomarkers and Personalized Medicine Association Study of the let-7 miRNA-Complementary Site Variant in the 3 0 Untranslated Region of the KRAS Gene in Stage III Colon Cancer ( NCCTG N 0147 Clinical Trial )

D. Sargent, R. Diasio, Adam M. Lee, 2014 .

K-ras Inhibitors and Pancreatic Cancer

S. Alberts, 2008 .

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

D. Sargent, R. Goldberg, A. Shields, 2016, The Oncologist.

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical Cancer Research.

Incidence of KRAS status in ongoing adjuvant trials in colon cancer

P. Laurent-Puig, S. Alberts, J. Taieb, 2009 .

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

S. Alberts, S. Lazzi, F. Ou, 2020, Translational oncology.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials

D. Sargent, S. Thibodeau, K. Pogue-Geile, 2017, JAMA oncology.

Flutamide in Men with Prostatic Intraepithelial Neoplasia: A Randomized, Placebo-Controlled Chemoprevention Trial

D. Bostwick, M. Blute, P. Novotny, 2006, American journal of therapeutics.

Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer.

Heidi Nelson, H. Nelson, S. Alberts, 2011, International journal of radiation oncology, biology, physics.

Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)

J. Meyerhardt, E. Giovannucci, S. Alberts, 2019, International journal of cancer.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

D. Sargent, M. Delorenzi, R. Lothe, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

D. Sargent, M. Delorenzi, S. Thibodeau, 2015, Gastroenterology.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical colorectal cancer.

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

S. Dakhil, S. Alberts, M. Lopatin, 2014, The oncologist.

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

D. Sargent, S. Thibodeau, M. Bertagnolli, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers

D. Sargent, S. Thibodeau, N. Foster, 2008, Clinical Cancer Research.

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

D. Moore, N. Foster, S. Alberts, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

P. Catalano, J. Berlin, D. Cella, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

J. Sloan, R. Goldberg, S. Alberts, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

David Cella, Lynne Wagner, Christopher H Crane, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.

D. Sargent, R. Goldberg, M. O’connell, 2009, Clinical colorectal cancer.

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2015 .

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

D. Sargent, F. Penault-Llorca, R. Goldberg, 2017, Journal of the National Cancer Institute.

Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.

David P Steensma, P. Novotny, J. Sloan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.

D. Sargent, S. Thibodeau, R. Goldberg, 2015, Journal of the National Cancer Institute.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Charles R. Thomas, L. Dawson, M. Thomas, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial)

D. Sargent, R. Diasio, Adam M. Lee, 2014, Clinical Cancer Research.

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)

Alvin C. Silva, M. Borad, N. Foster, 2021, Investigational New Drugs.

FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience

G. Gores, M. Borad, L. Roberts, 2021, JCO precision oncology.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 2.2019: Featured Updates to the NCCN Guidelines

J. Sicklick, J. Vauthey, A. Benson, 2019 .

B. O'neill, B. Mokri, S. Alberts, 1999, Leukemia & lymphoma.

MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer

Kazuhiro Yoshida, S. Alberts, F. Sinicrope, 2017, Scientific Reports.

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

T. Smyrk, N. Foster, S. Alberts, 2019, The oncologist.

EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.

W. Bamlet, A. Oberg, N. Takahashi, 2017, Gastrointestinal endoscopy.

Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer

J. Cerhan, D. Sargent, S. Thibodeau, 2009, Cancer Epidemiology, Biomarkers & Prevention.

OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.

S. Curley, J. Kahan, B. Nordlinger, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

C. Köhne, G. Folprecht, S. Alberts, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Journal of the National Cancer Institute.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.

J. Sicklick, J. Vauthey, A. Benson, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

OncoSurge: a strategy for long‐term survival in metastatic colorectal cancer

S. Alberts, G. Poston, Graeme J. Poston, 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail.

D. Shibata, L. Burgart, S. Alberts, 1994, Cancer research.

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

D. Sargent, R. Goldberg, A. Grothey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas

T. Grogan, S. Thibodeau, T. Smyrk, 2013, Cancer.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

J. Meyerhardt, C. Willett, C. Fuchs, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lixin Lang, S. Alberts, K. Papadopoulos, 2010 .

Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)

K. Owzar, M. Ratain, C. Willet, 2021, Pharmacogenetics and genomics.

Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma

T. Therneau, W. Kim, G. Gores, 2012, Hepatology.

MiR-320e is a novel prognostic biomarker in colorectal cancer

C. Boland, A. Oberg, S. Alberts, 2015, British Journal of Cancer.

Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance).

D. Sargent, S. Thibodeau, R. Goldberg, 2017, Journal of gastrointestinal oncology.

Chemotherapy for colorectal cancer liver metastases.

S. Alberts, L. Wagman, 2008, The oncologist.

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

J. Sloan, R. Goldberg, S. Alberts, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment options for hepatobiliary and pancreatic cancer.

G. Gores, M. Kendrick, L. Roberts, 2007, Mayo Clinic proceedings.

Gastric cancer in Alaska Native people: A cancer health disparity

S. Alberts, H. Martinson, M. Olnes, 2018, World journal of gastroenterology.

History of the development of antiemetic guidelines at Mayo Clinic Rochester.

P. Southorn, D. Farley, C. Loprinzi, 2000, Mayo Clinic proceedings.

716 EUS Guided Intra-Tumoral Gemcitabine Therapy for Locally Advanced and Metastatic Pancreatic Cancer

D. Mukhopadhyay, N. Takahashi, M. Farnell, 2011 .

Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

D. Sargent, C. Fuchs, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

S. Alberts, John W. Park, M. Melisko, 2009, Clinical Cancer Research.

Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.

S. Alberts, B. Lanpher, T. Halfdanarson, 2019, Journal of gastrointestinal oncology.

North Central Cancer Treatment Group--achievements and perspectives.

E. Perez, J. Buckner, D. Sargent, 2008, Seminars in oncology.

Phase II trial of dolastatin-10 in patients with advanced breast cancer

E. Perez, J. Krook, S. Dakhil, 2005, Investigational New Drugs.

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

D. Sargent, P. Philip, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

A. Grothey, S. Dakhil, S. Alberts, 2020, Therapeutic advances in medical oncology.

A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer

J. Sloan, R. Goldberg, S. Alberts, 2002, Investigational New Drugs.

CPT-11 for bile-duct and gallbladder carcinoma

R. Goldberg, L. Burgart, S. Alberts, 2002, International journal of gastrointestinal cancer.

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

J. Sloan, S. Alberts, C. Erlichman, 2005, Anti-cancer drugs.

Is There a Role for Liver Transplantation in the Treatment of Patients With Metastatic Colorectal Cancer?

D. Nagorney, S. Alberts, C. Rosen, 2019, Annals of surgery.

A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.

R. Houlston, S. Gallinger, P. Newcomb, 2021, European journal of cancer.

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.

Stephanie A. Bien, A. Joshi, Wei Sun, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study

James Y. Dai, H. Brenner, J. Chang-Claude, 2021, Cancer Epidemiology, Biomarkers & Prevention.

A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults

L. Hartmann, T. Rummans, J. Sloan, 2010, Cancer Management and Research.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

A. Benson, J. Galon, R. Goldberg, 2020, JNCI Cancer Spectrum.

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

D. Sargent, S. Thibodeau, R. Goldberg, 2015, Clinical Cancer Research.

Solid Pseudopapillary Neoplasms of the Pancreas: A Large American Cohort.

T. Smyrk, S. Alberts, R. McWilliams, 2019, Pancreas.

Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas

D. Nagorney, S. Alberts, T. Halfdanarson, 2018, Pancreas.

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer

J. Hornberger, S. Dakhil, S. Alberts, 2014, PharmacoEconomics.

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

D. Sargent, R. Diasio, Adam M. Lee, 2014, Journal of the National Cancer Institute.

Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer

S. Alberts, C. Verschraegen, M. Markham, 2023, JCO oncology practice.

Cancer of the Liver and Bile Ducts

G. Gores, M. Kendrick, D. Nagorney, 2006 .

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Daniel J Sargent, Greg Yothers, Lindsay A Renfro, 2014, Journal of the National Cancer Institute.

Hepatobiliary cancers, version 1.2017 featured updates to the NCCN guidelines

J. Sicklick, J. Vauthey, A. Benson, 2017 .

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

R. Labianca, D. Kerr, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic web‐based models for stage II and III colon cancer

D. Sargent, A. Bardia, C. Loprinzi, 2011, Cancer.

Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma

T. Therneau, G. Gores, N. LaRusso, 2013, CardioVascular and Interventional Radiology.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

D. Sargent, R. Diasio, Adam M. Lee, 2016, Pharmacogenetics and genomics.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

D. Sargent, P. Newcomb, R. Goldberg, 2016, International Journal of Cancer.

Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.

D. Sargent, P. Newcomb, S. Alberts, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2020, JCO precision oncology.

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

R. Labianca, J. Meyerhardt, E. Oki, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!).

D. Sargent, A. Bardia, C. Loprinzi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant and adjuvant therapy combined with resection of hepatic colorectal cancer metastases

S. Alberts, 2006 .

Treatment of Liver-Limited Metastatic Colorectal Cancer

S. Alberts, J. Hubbard, 2010, Cancer journal.

Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147.

D. Sargent, S. Thibodeau, T. Smyrk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.

D. Nagorney, T. Smyrk, S. Alberts, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2020, European Journal of Cancer.

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

A. Biankin, S. Domchek, R. Wolff, 2016 .

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, J. Sloan, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do we need biologic agents in preoperative systemic therapy of liver metastases?

S. Alberts, 2009 .

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.

R. Labianca, R. Goldberg, C. Lepage, 2022, European journal of cancer.

Timing Means Everything, Maybe

S. Alberts, 2009, Annals of surgical oncology.

Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers.

M. Clark, T. Rummans, J. Sloan, 2015, Journal of pain and symptom management.

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX)

D. Sargent, R. Goldberg, A. Grothey, 2007, Cancer.

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

D. Sargent, C. Fuchs, R. Goldberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma.

Kenneth K Wang, M. Henry, N. Takahashi, 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741.

D. Sargent, H. McLeod, C. Fuchs, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver: A North Central Cancer Treatment Group (NCCTG) phase II intergroup trial.

D. Sargent, J. Donohue, S. Alberts, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evolving role of chemotherapy in resected liver metastases.

S. Alberts, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)

Wei Sun, P. Newcomb, U. Peters, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Elderly patients with metastatic esophageal/gastric cancer: A pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials

D. Sargent, N. Foster, S. Dakhil, 2008 .

Update on the optimal management of patients with colorectal liver metastases.

S. Alberts, 2012, Critical reviews in oncology/hematology.

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.

D. Sargent, S. Thibodeau, R. Goldberg, 2016 .

Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Preliminary Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: North Central Cancer Treatment Group (N0044)

H. McLeod, D. Moore, N. Foster, 2007, American journal of clinical oncology.

Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas.

J. Donohue, S. Alberts, V. Trastek, 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma

G. Gores, P. Novotny, T. Sio, 2012, American journal of clinical oncology.

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

R. Labianca, D. Sargent, E. Van Cutsem, 2016, Journal of geriatric oncology.

Metastatic colorectal cancer: Therapeutic options

S. Alberts, S. Patiyil, 2006, Current treatment options in oncology.

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

R. Fonseca, K. Rowland, S. Dakhil, 2004 .

Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer

P. Novotny, J. Sloan, C. Fuchs, 2023, Cancer control : journal of the Moffitt Cancer Center.

Updated options for liver-limited metastatic colorectal cancer.

S. Alberts, 2008, Clinical colorectal cancer.

Use of neoadjuvant and postoperative chemotherapy with surgical resection of colorectal cancer hepatic metastases

S. Alberts, 2008 .

Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.

V. Lowe, N. Foster, A. Grothey, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Final results of hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic (M-CRC) to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study.

D. Sargent, D. Nagorney, M. O’connell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

M. Borad, L. Roberts, T. Smyrk, 2017, Targeted Oncology.

Pancreatic cancer in the older patient.

M. O’connell, S. Alberts, S. Jacobson, 2001, Oncology.

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.

J. Crowley, P. Catalano, M. Leblanc, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

75 – Cancer of the Stomach and Gastroesophageal Junction

S. Alberts, J. Ashman, L. Gunderson, 2013 .

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

D. Moore, N. Foster, K. Rowland, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract A55: A first‐in‐human, phase I study of an oral hedgehog pathway antagonist, BMS‐833923 (XL139), in subjects with advanced or metastatic solid tumors

A. Tolcher, Lixin Lang, S. Alberts, 2009 .

Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma.

M. Borad, L. Roberts, S. Alberts, 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Prospective Assessment of Rectal Cancer Staging and Clinical Management with Both Radial and Linear EUS

Kenneth K Wang, H. Nelson, A. Clayton, 2005 .

Genome‐wide study of genetic polymorphisms predictive for outcome from first‐line oxaliplatin‐based chemotherapy in colorectal cancer patients

J. Chang-Claude, M. Hoffmeister, P. Seibold, 2023, International journal of cancer.

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials

P. Laurent-Puig, E. Van Cutsem, R. Goldberg, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance)

D. Sargent, P. Newcomb, R. Goldberg, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Gemcitabine plus cisplatin in advanced pancreatic cancer.

S. Alberts, R. McWilliams, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma.

D. Moore, N. Foster, S. Alberts, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Liver-Limited Metastatic Colorectal Cancer

S. Alberts, J. Hubbard, 2010, Cancer journal.

Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

T. Smyrk, S. Alberts, M. Mahoney, 2013 .

Update on the optimal management of patients with colorectal liver metastases.

S. Alberts, 2012, Critical reviews in oncology/hematology.

Chemotherapy for colorectal cancer liver metastases.

S. Alberts, L. Wagman, 2008, The oncologist.

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C.

J. T. Reynolds, B. Bot, A. Grothey, 2010 .

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

M. Borad, N. Foster, S. Alberts, 2023, The oncologist.

Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943

N. Foster, J. Kugler, S. Alberts, 2007, Journal of gastrointestinal cancer.

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

D. Kerr, M. Bertagnolli, P. Rougier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

J. Donohue, J. Kugler, S. Alberts, 2008 .

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

P. Catalano, S. Alberts, E. Mitchell, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.